Nelson, Peter T., Kryscio, Richard J., Abner, Erin L., Schmitt, Frederick A., Jicha, Gregory A., Mendiondo, Marta S., Cooper, Greg, Smith, Charles B., Markesbery, William R.

Dementia can be caused by different diseases including Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), or both (AD + DLB). University of Kentucky AD Center pathologically-diagnosed AD and AD + DLB cases were evaluated who had three or more longitudinal antemortem mental status examinations (n = 156). Patients with important concomitant pathology (n = […]

Froelich, Lutz, Andreasen, Niels, Tsolaki, Magda, Foucher, Arnaud, Kavanagh, Shane, Van Baelen, Bart, Schwalen, Susanne

Objective: The International Outcomes Survey in Dementia (IOSID) was initiated to observe the effects of current standard of care for Alzheimer’s disease (AD) on patient outcomes and caregiver burden in a real-life setting. Research design and methods: This 2-year, international, prospective, longitudinal and observational cohort survey involved patients with mild-to-moderate AD (Mini-Mental State Examination [MMSE] […]

Campbell, Noll L., Dexter, Paul, Perkins, Anthony J., Gao, Sujuan, Li, Lang, Skaar, Todd C., Frame, Amie, Hendrie, Hugh C., Callahan, Chris M., Boustani, Malaz A.

Background: The class of acetylcholinesterase inhibitors (ChEI), including donepezil, rivastigmine, and galantamine, have similar efficacy profiles in patients with mild to moderate Alzheimer’s disease (AD). However, few studies have evaluated adherence to these agents. We sought to prospectively capture the rates and reasons for nonadherence to ChEI and determine factors influencing tolerability and adherence.; Methods/design: […]

Beauchet, Olivier, Launay, Cyrille P., Allali, Gazan, Watfa, Gilles, Gallouj, Karim, Herrmann, François R., Annweiler, Cedric

Background: Anti-dementia drugs may improve gait performance. No comparison between acetylcholinesterase inhibitors (CEIs) and memantine-related changes in gait variability has been reported. The objectives of this study were to 1) quantify and compare the mean values and coefficients of variation (CoV) of stride time in demented patients with Alzheimer’s disease and related disorders (ADRD) before […]

Boxer, Adam L., Lipton, Anne M., Womack, Kyle, Merrilees, Jennifer, Neuhaus, John, Pavlic, Danijela, Gandhi, Anisha, Red, Dana, Martin-Cook, Kristen, Svetlik, Doris, Miller, Bruce L.

There are currently no Food and Drug Administration-approved treatments for frontotemporal lobar degeneration (FTLD). The objectives of this study were to explore the tolerability of memantine treatment in FTLD and to monitor for possible effects on behavior, cognition, and function. Forty-three individuals who met clinical criteria for FTLD [21 with frontotemporal dementia (FTD), 13 with […]

Santoro, Aurelia, Siviero, Paola, Minicuci, Nadia, Bellavista, Elena, Mishto, Michele, Olivieri, Fabiola, Marchegiani, Francesca, Chiamenti, Andrea Maria, Benussi, Luisa, Ghidoni, Roberta, Nacmias, Benedetta, Bagnoli, Silvia, Ginestroni, Andrea, Scarpino, Osvaldo, Feraco, Emidio, Gianni, Walter, Cruciani, Guido, Paganelli, Roberto, Di Iorio, Angelo, Scognamiglio, Mario, Grimaldi, Luigi Maria Edoardo, Gabelli, Carlo, Sorbi, Sandro, Binetti, Giuliano, Crepaldi, Gaetano, Franceschi, Claudio

Acetylcholinesterase inhibitors (AChEIs) have been used to improve cognitive status and disability in patients with mild to moderate Alzheimer’s disease (AD). However, while the efficacy of AChEIs (i.e. how they act in randomized controlled trials) in this setting is widely accepted, their effectiveness (i.e. how they behave in the real world) remains controversial. To compare […]

Feldman, Howard H., Pirttila, Tuula, Dartigues, Jean-François, Everitt, Brian, Van Baelen, Bart, Schwalen, Susanne, Kavanagh, Shane

Objective: This study evaluated patient and treatment (galantamine and other acetylcholinesterase inhibitors (AChEIs)) factors associated with the time until nursing home placement (NHP) in patients with Alzheimer’s disease (AD) with and without cerebrovascular disease (CVD).; Methods: Re-contact follow-up study conducted in 2004 of 548 patients who had previously participated in RCTs with galantamine. Time to […]

Gareri, Pietro, Putignano, Daria, Castagna, Alberto, Cotroneo, Antonino Maria, De Palo, Grazia, Fabbo, Andrea, Forgione, Luigi, Giacummo, Attilio, Lacava, Roberto, Marino, Saverio, Simone, Maurizio, Zurlo, Amedeo, Putignano, Salvatore

Background: Combined therapy of memantine and acetylcholinesterase inhibitors (AChEIs) in patients with Alzheimer’s disease (AD) may be associated with higher benefits than either monotherapy.; Objective: This retrospective multicentric study conducted in seven Italian Ambulatory Centers for Dementia assessed the efficacy and safety of memantine 20 mg/day administered for 6 months in addition to an AChEI […]

Beauchet, Olivier, Launay, Cyrille P., Allali, Gilles, Herrmann, François R., Annweiler, Cedric

Background: No comparison of anti-dementia drugs-related gait changes has been previously conducted combining single and dual task assessments.; Objectives: (1) To quantify and compare gait changes among patients with possible or probable Alzheimer’s disease before and after the use of acetylcholinesterase inhibitors (i.e., donepezil, galantamine, rivastigmine) or memantine, and among controls with possible or probable […]